Monte Rosa Therapeutics Inc
GLUE4.845USD
+0.055+1.14%
交易中 （美東）報價延遲15分鐘
298.00M總市值
48.43本益比TTM
關於 Monte Rosa Therapeutics Inc 公司
Monte Rosa Therapeutics, Inc. 是一家臨牀階段的生物技術公司。該公司致力於爲患有腫瘤和自身免疫等領域嚴重疾病的患者開發一系列新型分子膠降解劑 (MGD)。MGD 是小分子藥物，利用人體天然的蛋白質破壞機制選擇性地降解治療相關蛋白質。該公司開發了一種降解平臺，稱爲定量和工程化消除新底物 (QuEEN)，以實現以目標爲中心的 MGD 發現和開發方法以及 MGD 產品候選物的合理設計。其產品候選物 MRT-2359 是一種口服生物可利用的 MGD，靶向翻譯終止因子蛋白 GSPT1。MRT-2359 正在進行臨牀開發，可能用於 MYC 驅動的腫瘤，包括轉移性非小細胞肺癌、小細胞肺癌和神經內分泌腫瘤。其其他產品候選物包括 MRT-6160 和 MRT-8102。
公司簡介
公司代碼GLUE
公司名稱Monte Rosa Therapeutics Inc
上市日期Jun 24, 2021
CEODr. Markus Warmuth, M.D.
員工數量134
證券類型Ordinary Share
年結日Jun 24
公司地址321 Harrison Avenue
城市BOSTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02118
電話16179492643
網址https://www.monterosatx.com/
公司代碼GLUE
上市日期Jun 24, 2021
CEODr. Markus Warmuth, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Anthony M. Manning, Ph.D.
Dr. Anthony M. Manning, Ph.D.
Independent Director
Independent Director
--
--
Ms. Christine Siu
Ms. Christine Siu
Independent Director
Independent Director
--
--
Dr. Chandra P. Leo, M.D.
Dr. Chandra P. Leo, M.D.
Independent Director
Independent Director
--
--
Dr. Andrew N. (Drew) Schiff, M.D.
Dr. Andrew N. (Drew) Schiff, M.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Sharon Townson, Ph.D.
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
36.00K
--
Ms. Jennifer Champoux
Ms. Jennifer Champoux
Chief Operating Officer
Chief Operating Officer
30.00K
--
Dr. Filip Janku, M.D., Ph.D.
Dr. Filip Janku, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
9.19K
-74.47%
Dr. Philip Nickson, J.D., Ph.D.
Dr. Philip Nickson, J.D., Ph.D.
Chief Business and Legal Officer
Chief Business and Legal Officer
--
-100.00%
Dr. Kimberly L. Blackwell, M.D.
Dr. Kimberly L. Blackwell, M.D.
Independent Director
Independent Director
--
--
Dr. Markus Warmuth, M.D.
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 7月28日 週一
更新時間: 7月28日 週一
持股股東
股東類型
持股股東
持股股東
佔比
New Enterprise Associates (NEA)
12.51%
T. Rowe Price Associates, Inc.
10.66%
BVF Partners L.P.
9.20%
Versant Ventures
9.19%
Baker Bros. Advisors LP
7.99%
Other
50.45%
持股股東
持股股東
佔比
New Enterprise Associates (NEA)
12.51%
T. Rowe Price Associates, Inc.
10.66%
BVF Partners L.P.
9.20%
Versant Ventures
9.19%
Baker Bros. Advisors LP
7.99%
Other
50.45%
股東類型
持股股東
佔比
Investment Advisor
32.75%
Hedge Fund
25.10%
Venture Capital
24.08%
Investment Advisor/Hedge Fund
17.31%
Research Firm
1.15%
Individual Investor
0.85%
Sovereign Wealth Fund
0.72%
Pension Fund
0.11%
Bank and Trust
0.10%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
229
62.87M
102.21%
-2.01M
2025Q1
235
60.82M
98.88%
-7.09M
2024Q4
220
61.73M
100.63%
-766.83K
2024Q3
200
57.64M
94.07%
-4.29M
2024Q2
191
55.42M
93.92%
+8.23M
2024Q1
185
49.41M
98.58%
+2.43M
2023Q4
187
49.83M
99.64%
+961.54K
2023Q3
187
51.89M
104.49%
+4.85M
2023Q2
202
40.69M
82.04%
-4.78M
2023Q1
192
47.34M
97.38%
+2.16M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
New Enterprise Associates (NEA)
7.69M
12.51%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
6.56M
10.66%
-475.63K
-6.76%
Mar 31, 2025
BVF Partners L.P.
5.66M
9.2%
+1.27M
+28.84%
Mar 31, 2025
Versant Ventures
5.65M
9.19%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
4.92M
7.99%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
4.67M
7.6%
-874.34K
-15.76%
Mar 31, 2025
Avoro Capital Advisors LLC
4.65M
7.55%
+300.55K
+6.92%
Mar 31, 2025
Suvretta Capital Management, LLC
3.36M
5.46%
+1.80M
+114.86%
Apr 09, 2025
BlackRock Institutional Trust Company, N.A.
3.22M
5.24%
-73.74K
-2.24%
Mar 31, 2025
The Vanguard Group, Inc.
3.10M
5.04%
-56.32K
-1.78%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.83%
Royce Quant Small-Cap Quality Value ETF
0.19%
iShares Micro-Cap ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
Avantis US Small Cap Equity ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.83%
Royce Quant Small-Cap Quality Value ETF
佔比0.19%
iShares Micro-Cap ETF
佔比0.05%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
Avantis US Small Cap Equity ETF
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
ProShares UltraPro Russell2000
佔比0.01%
iShares Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
